[go: up one dir, main page]

WO2006089861A3 - Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission - Google Patents

Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission Download PDF

Info

Publication number
WO2006089861A3
WO2006089861A3 PCT/EP2006/060060 EP2006060060W WO2006089861A3 WO 2006089861 A3 WO2006089861 A3 WO 2006089861A3 EP 2006060060 W EP2006060060 W EP 2006060060W WO 2006089861 A3 WO2006089861 A3 WO 2006089861A3
Authority
WO
WIPO (PCT)
Prior art keywords
dithiolethiones
dysfunction
treatment
conditions associated
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/060060
Other languages
French (fr)
Other versions
WO2006089861A2 (en
Inventor
Benjamin Drukarch
Anton N M Schoffelmeer
Roelof W Feenstra
Marie-Odile Christen
Jean-Louise Burgot
Marylene Chollet
Bakker Wouter I Iwema
Vliet Bernard J Van
Martinus Th M Tulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0609043-5A priority Critical patent/BRPI0609043A2/en
Priority to CA002594165A priority patent/CA2594165A1/en
Priority to MX2007010380A priority patent/MX2007010380A/en
Priority to AU2006218012A priority patent/AU2006218012A1/en
Priority to EP06708351A priority patent/EP1858875A2/en
Priority to CN2006800030655A priority patent/CN101107240B/en
Priority to JP2007556592A priority patent/JP2008531519A/en
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of WO2006089861A2 publication Critical patent/WO2006089861A2/en
Publication of WO2006089861A3 publication Critical patent/WO2006089861A3/en
Priority to IL184128A priority patent/IL184128A0/en
Anticipated expiration legal-status Critical
Priority to NO20074840A priority patent/NO20074840L/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to dithiolethiones derivatives as monoamino oxidase inhibitors, in particular MAO-B inhibitors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said dithiolethiones derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment, amelioration or prevention of conditions associated with dysfunction of monoamine neurotransmission. The compounds have the general formula (1) wherein the symbols have the meanings given in the specification.
PCT/EP2006/060060 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission Ceased WO2006089861A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002594165A CA2594165A1 (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
MX2007010380A MX2007010380A (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission.
AU2006218012A AU2006218012A1 (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
EP06708351A EP1858875A2 (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
CN2006800030655A CN101107240B (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
BRPI0609043-5A BRPI0609043A2 (en) 2005-02-24 2006-02-17 use of a compound, compound, pharmaceutical composition, and method for the preparation of pharmaceutical compositions
JP2007556592A JP2008531519A (en) 2005-02-24 2006-02-17 Anethole dithiolthione and other dithiolthiones for the treatment of symptoms associated with dysfunction of monoamine neurotransmission
IL184128A IL184128A0 (en) 2005-02-24 2007-06-21 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
NO20074840A NO20074840L (en) 2005-02-24 2007-09-24 Anethole dithioltion and other dithiolthiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65542805P 2005-02-24 2005-02-24
US60/655,428 2005-02-24
EP05101405.8 2005-02-24
EP05101405 2005-02-24

Publications (2)

Publication Number Publication Date
WO2006089861A2 WO2006089861A2 (en) 2006-08-31
WO2006089861A3 true WO2006089861A3 (en) 2006-10-26

Family

ID=34938805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/060060 Ceased WO2006089861A2 (en) 2005-02-24 2006-02-17 Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission

Country Status (14)

Country Link
EP (1) EP1858875A2 (en)
JP (1) JP2008531519A (en)
KR (1) KR20070117607A (en)
CN (1) CN101107240B (en)
AR (1) AR055862A1 (en)
AU (1) AU2006218012A1 (en)
BR (1) BRPI0609043A2 (en)
CA (1) CA2594165A1 (en)
MX (1) MX2007010380A (en)
RU (1) RU2402543C2 (en)
SA (1) SA06270023B1 (en)
TW (1) TW200640898A (en)
UA (1) UA94579C2 (en)
WO (1) WO2006089861A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
CN102807557B (en) * 2012-08-21 2015-02-04 苏州大学 3H-1,2-dithio-cyclopentene-3-thioketone compound and application thereof
KR101438415B1 (en) * 2013-07-25 2014-09-17 동국대학교 경주캠퍼스 산학협력단 Extract of Uncaria rhynchophylla for preventing or ameliorating the memory impairment
CN104788440B (en) * 2015-04-03 2017-12-26 苏州大学 Nicotinic acid derivates and its application
JP2020511450A (en) 2017-03-07 2020-04-16 オーピーツー ドラッグス Desmethylanethole trithione derivative for the treatment of diseases associated with mitochondrial reactive oxygen species (ROS) production
FR3063640B1 (en) * 2017-03-07 2020-10-09 Elodie Petitjean TREATMENT OF PULMONARY FIBROSIS USING A SELECTIVE INHIBITOR OF THE PRODUCTION OF REACTIVE OXYGEN SPECIES OF MITOCHONDRIAL ORIGIN
CN113694068A (en) * 2018-09-18 2021-11-26 St知识产权控股公司 Rotamers of 4-alkyl-5-heteroaryl-3H-1, 2-dithiole-3-thiones

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1442450A (en) * 1964-05-05 1966-06-17 Monsanto Chemicals New heterocyclic compounds containing sulfur
JPH01319477A (en) * 1988-06-20 1989-12-25 Mitsui Toatsu Chem Inc Novel 1,2-dithiol-3-thione derivative and immunomodulator containing the same as an active ingredient
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1442450A (en) * 1964-05-05 1966-06-17 Monsanto Chemicals New heterocyclic compounds containing sulfur
JPH01319477A (en) * 1988-06-20 1989-12-25 Mitsui Toatsu Chem Inc Novel 1,2-dithiol-3-thione derivative and immunomodulator containing the same as an active ingredient
WO1998027970A2 (en) * 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
WO2001009118A2 (en) * 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIANNINI F A ET AL: "in vitro-in vivo antifungal evaluation and structure-activity relationships of 3H-1,2-dithiole-3-thione derivatives", 2004, IL FARMACO, ROME, IT, PAGE(S) 245-254, ISSN: 0014-827X, XP002340529 *
PATENT ABSTRACTS OF JAPAN vol. 014, no. 118 (C - 0697) 6 March 1990 (1990-03-06) *
PEDERSEN C T: "The Formation of 1,2-Propadiene-1,3-dithione (Carbon disulfide) from Flash vacuum Pyrolysis of 1,2-dithiole-3-thiones", 1996, TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, PAGE(S) 4805-4808, ISSN: 0040-4039, XP002340528 *

Also Published As

Publication number Publication date
SA06270023B1 (en) 2010-10-12
RU2402543C2 (en) 2010-10-27
KR20070117607A (en) 2007-12-12
EP1858875A2 (en) 2007-11-28
SA06270023A (en) 2005-12-03
TW200640898A (en) 2006-12-01
AR055862A1 (en) 2007-09-12
CN101107240A (en) 2008-01-16
JP2008531519A (en) 2008-08-14
CN101107240B (en) 2011-02-09
UA94579C2 (en) 2011-05-25
CA2594165A1 (en) 2006-08-31
AU2006218012A1 (en) 2006-08-31
WO2006089861A2 (en) 2006-08-31
BRPI0609043A2 (en) 2010-11-16
RU2007135184A (en) 2009-03-27
MX2007010380A (en) 2007-09-25

Similar Documents

Publication Publication Date Title
WO2010005958A3 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
WO2007140385A3 (en) Thiazole compounds as cannabinoid receptor ligands and uses thereof
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2006092213A8 (en) Pyrazolylcarboxanilides
WO2008036653A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A3 (en) N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
WO2007024949A3 (en) Alpha2c adrenoreceptor agonists
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
WO2006105888A3 (en) Synergistic fungicidal active substance combinations
WO2007127726A3 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2006099941A8 (en) Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
WO2007025709A3 (en) Organic compounds
ATE519373T1 (en) TEA COMPOSITION AND PROCESS FOR PRODUCTION THEREOF
WO2005005389A3 (en) Malonamide derivatives
WO2007126900A3 (en) Antifungal agents
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2006116218A8 (en) Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2006089861A3 (en) Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
WO2007017728A3 (en) Novel heterocyclic compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 184128

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12007501413

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2006708351

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2594165

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200680003065.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006218012

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3692/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/010380

Country of ref document: MX

Ref document number: 2007556592

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006218012

Country of ref document: AU

Date of ref document: 20060217

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006218012

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: DZP2007000593

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 1020077021935

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007135184

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 184128

Country of ref document: IL

WWP Wipo information: published in national office

Ref document number: 2006708351

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609043

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20070824